<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7347348\results\search\testTrace\results.xml">
  <result pre="in Oncology/Hematology1040-84281879-0461Elsevier B.V. pmcid: 7347348S1040-8428(20)30195-5 doi: 10.1016/j.critrevonc.2020.103059103059 : Article Coronavirus" exact="infection" post="and immune system: An insight of COVID-19 in cancer"/>
  <result pre="to prospectively collect data, to identify effective interventions to guide" exact="treatment" post="decision. Keywords Cancer Oncology COVID-19 Coronavirus Infection Immunotherapy 1"/>
  <result pre="of international concern. The most common clinical manifestations of SARS-CoV-2" exact="infection" post="are fever, cough, and dyspnea, however also muscle pain,"/>
  <result pre="processes, followed by post-operative immunosuppression (Menges et al., 2012). Long-lasting" exact="treatment" post="with high-dose corticosteroids, commonly used as supportive therapy for"/>
  <result pre="In clinical practice, preventive measures for subjects undergoing systemic anti-cancer" exact="treatment" post="are commonly implemented, as serologic screening for certain chronic"/>
  <result pre="subjects undergoing systemic anti-cancer treatment are commonly implemented, as serologic" exact="screening" post="for certain chronic infections (e.g. hepatitis B [HBV] and"/>
  <result pre="fight against tumor cells. ICIs have become part of standard" exact="treatment" post="for several solid tumors, as melanoma, non-small cell lung"/>
  <result pre="subjects, rather their immune system is reinforced by the oncologic" exact="treatment" post="they receive. This might translate into a distinct susceptibility"/>
  <result pre="health. The absence of approved vaccines or drugs for the" exact="treatment" post="of infections, together with the wide range of animal"/>
  <result pre="There is only one report on the features of MERS-CoV" exact="infection" post="among patients with cancer during the outbreak in 2015."/>
  <result pre="history of cancer (Liang et al., 2020). Authors comment this" exact="prevalence" post="is higher than that observed in the overall Chinese"/>
  <result pre="definition of cancer history does not distinguish long-term survivors with" exact="diagnosis" post="of previous cancer, from patients receiving active systemic treatment."/>
  <result pre="the epidemics, with lung cancer being fairly the most common" exact="diagnosis" post="(Zhang et al., 2020; Yu et al., 2020). However,"/>
  <result pre="the expression of pro-inflammatory factors (Kawai and Akira, 2010). CoV" exact="infection" post="promotes interferon (IFN) I synthesis and stimulation of signaling"/>
  <result pre="patients with confirmed COVID-19 compared difference in the expression of" exact="infection" post="related biomarkers between severe and non-severe cases (Qin et"/>
  <result pre="SARS-CoV and MERS-CoV infections (Mahallawi et al., 2018). Specifically, SARS-CoV-2" exact="infection" post="is characterized by persistent antigenic T cellsâ€™ activation leading"/>
  <result pre="COVID-19 case series are available to date, suggesting that cancer" exact="diagnosis" post="is under-represented in patients with COVID-19, compared with other"/>
  <result pre="B cells Dendritic cells Other cell populations, soluble mediators CoV" exact="infection" post="â†‘ cytokine production â†‘ activation â†‘ complement protein production"/>
  <result pre="Ig suppressor of T cell activation; 5FU, 5-fluorouracil. However, cancer" exact="treatment" post="has substantially changed over the last years, with less"/>
  <result pre="categories can be distinguished on the basis of the oncologic" exact="treatment" post="they receive and subsequent immune status impairment. The first"/>
  <result pre="treated with immunotherapy. For this latter group of patients, SARS-CoV-2" exact="infection" post="may represent a serious threat. In fact, the immune"/>
  <result pre="immune system of patients receiving immunotherapy is reinforced by the" exact="treatment" post="itself and might show aberrant responses to external factors."/>
  <result pre="(i.e. the cytokine storm), possibly worsening the outcomes of the" exact="infection" post="(Moore and June, 2020). In patients responding to treatment"/>
  <result pre="the infection (Moore and June, 2020). In patients responding to" exact="treatment" post="(accounting for 20â€&quot;40 % of patients across different studies),"/>
  <result pre="immune-related adverse events (irAEs) onset. Interestingly, immunosuppressive drugs for the" exact="treatment" post="of severe COVID-19 cases have become part of the"/>
  <result pre="become part of the therapeutic arsenal of oncologists for the" exact="treatment" post="of steroid-refractory severe irAEs (e.g. tocilizumab) (Kim et al.,"/>
  <result pre="virus (LCMV) (Barber et al., 2006). Preliminary results suggested that" exact="treatment" post="with anti-PD1 might improve the outcomes of patients with"/>
  <result pre="CD4â€¯+â€¯T cells, showing features of exhausted lymphocytes. Patients with SARS-CoV-2" exact="infection" post="have a markedly decreased number of NK and CD8â€¯+â€¯T"/>
  <result pre="dampened by the tumor (Sharma et al., 2017). Curiously, CoV" exact="infection" post="in humans shares the same mechanisms involved in immunotherapy"/>
  <result pre="between immune system of oncologic patients receiving immunotherapy and SARS-CoV-2" exact="infection" post="is extremely complex. What happens when a reinforced immune"/>
  <result pre="and at risk of infection. On the other hand, most" exact="treatment" post="procedures in oncology cannot be delayed without compromising the"/>
  <result pre="in oncology cannot be delayed without compromising the efficacy of" exact="treatment" post="itself, and in some cases the benefit of ensuring"/>
  <result pre="in some cases the benefit of ensuring a well-delivered anti-cancer" exact="treatment" post="plan outweighs the risk of COVID-19 infection. In the"/>
  <result pre="al., 2020). For patients receiving active oncologic treatments, customization of" exact="treatment" post="strategy is needed in order to minimize their presence"/>
  <result pre="with the implementation of such measures, prioritization of patients by" exact="diagnosis" post="and/or type of anticancer treatment should be pursued. Patients"/>
  <result pre="measures, prioritization of patients by diagnosis and/or type of anticancer" exact="treatment" post="should be pursued. Patients with lung cancer diagnosis seem"/>
  <result pre="of anticancer treatment should be pursued. Patients with lung cancer" exact="diagnosis" post="seem to be more at risk for severe COVID-19,"/>
  <result pre="pandemic on the basis of a risk assessment for cancer" exact="treatment" post="delay. Decision regarding surgery, radiotherapy and medical treatment delays"/>
  <result pre="for cancer treatment delay. Decision regarding surgery, radiotherapy and medical" exact="treatment" post="delays are made after a risk-to-benefit evaluation between the"/>
  <result pre="elements to consider in decision making are the intent of" exact="treatment" post="strategy (i.e. curative vs non-curative), and the patientsâ€™ life"/>
  <result pre="immunotherapy (i.e. with primary/acquired resistance). Furthermore, no markers for early" exact="diagnosis" post="can be used to guide decision making in the"/>
  <result pre="rationale supporting the role of the immune system in CoV" exact="infection" post="and patients with cancer, with a complex interplay between"/>
  <result pre="as an integrative tool to guide the risk-to-benefit consideration and" exact="treatment" post="decision in specific subgroups of patients. Customization of cancer"/>
  <result pre="treatment decision in specific subgroups of patients. Customization of cancer" exact="treatment" post="should be pursued, in order to provide patients with"/>
  <result pre="of thoracic RT* NO vs YES Treatment characteristics Line of" exact="treatment" post="Adjuvant vs metastatic Type of treatment HT/TT/TKIs/mAb vs CT"/>
  <result pre="Treatment characteristics Line of treatment Adjuvant vs metastatic Type of" exact="treatment" post="HT/TT/TKIs/mAb vs CT vs IT/CTâ€¯+â€¯IT History of irAEs** NO"/>
  <result pre="diabetes, chronic obstructive pulmonary disease, chronic systemic infections. bConcomitant steroid" exact="treatment" post="includes continuous therapy with &amp;gt;10 mg daily of prednisone"/>
  <result pre="that this risk might be different depending on the oncologic" exact="treatment" post="received. There is a strong rationale supporting an increased"/>
  <result pre="a potential higher risk for those experiencing disease responses to" exact="treatment" post="and/or with a history of irAEs. However, with data"/>
  <result pre="collect data, in order to identify effective interventions to guide" exact="treatment" post="decision during the pandemic. Funding This work was partially"/>
  <result pre="receptors in innate immunity: update on Toll-like receptorsNat. Immunol.115201037338420404851 KimS.T.TayarJ.TrinhV.A.Suarez-AlmazorM.Successful" exact="treatment" post="of arthritis induced by checkpoint inhibitors with tocilizumab: a"/>
  <result pre="severity of COVID-19 in patients with lung cancerCancer Discov.202010.1158/2159-8290.CD-20-0596CD-20-0596 MahallawiW.H.KhabourO.F.ZhangQ.MERS-CoV" exact="infection" post="in humans is associated with a pro-inflammatory Th1 and"/>
  <result pre="of COVID-19 for patients with cancerLancet Oncol.2142020e18032142622 YingT.LiW.DimitrovD.S.Discovery of T-Cell" exact="infection" post="and apoptosis by middle east respiratory syndrome coronavirusJ. Infect."/>
 </snippets>
</snippetsTree>
